![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Sofosbuvir and Ledipasvir/Sofosbuvir for the Treatment of Patients With Chronic
Genotype 6 Hepatitis C Virus Infection: Integrated Analysis of Phase 2 and Phase 3 Studies
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Ed J. Gane,1 Wan-Long Chuang,2 Tarek Hassanein,3 Kris V. Kowdley,4 Eric Lawitz,5 Bing Gao,6 Hongmei Mo,6 Rob Hyland,6 Jenny C. Yang,6 Shampa De-Oertel,6 Diana Brainard,6 Steven J. Knox,6 John G. McHutchison,6 Ching-Lung Lai,7 Henry Lik-Yuen Chan8
1Auckland City Hospital, Auckland, New Zealand; 2Kaohsiung Medical University, Kaohsiung, Taiwan; 3Southern California Liver Center, Coronado, CA; 4Swedish Medical Center, Seattle, WA; 5The Texas Liver Institute, UT Health Science Center, San Antonio, TX; 6Gilead Sciences, Inc., Foster City, CA; 7Queen Mary Hospital, Hong Kong; 8The Chinese University of Hong Kong
![AASLD1.gif](../images/120815/120815-2/AASLD1.gif)
![AASLD2.gif](../images/120815/120815-2/AASLD2.gif)
![AASLD3.gif](../images/120815/120815-2/AASLD3.gif)
![AASLD4.gif](../images/120815/120815-2/AASLD4.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|